MSF Releases New Report On DR-TB Treatment, Urges Company To Halve Price Of Newer TB Drug Bedaquiline

Médecins Sans Frontières: High prices restrict access to best drug-resistant tuberculosis treatment
“People with drug-resistant tuberculosis (DR-TB) continue to be deprived of today’s best-possible treatment in part because of high drug prices, according to a new report — DR-TB Drugs Under the Microscope — released [Tuesday] by Médecins Sans Frontières (MSF) at the 49th Union World Conference on Lung Health in The Hague. MSF is calling, in particular, on U.S. pharmaceutical corporation Johnson & Johnson (J&J) to cut the price of the newer TB drug bedaquiline in half, so more lives can be saved…” (10/23).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.